Cited 0 times in
Interim Results of the Phase 1 Study of Tnb-486, a Novel CD19xCD3 T-Cell Engager, in Patients with Relapsed/Refractory (R/R) B-NHL
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.